NCT01628913 - Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Pancreatic Neuroendocrine Tumors (pNET)

Interventions

DRUG

BEZ235

BEZ235 400 mg bid p.o. (by mouth, twice daily)

DRUG

Everolimus

Everolimus 10 mg qd p.o. (by mouth, daily)

Trial Locations (26)

6000

Novartis Investigative Site, Lucerne

10467

Montefiore Medical Center SC, The Bronx

28034

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

31054

Novartis Investigative Site, Toulouse

34298

Novartis Investigative Site, Montpellier

40138

Novartis Investigative Site, Bologna

41013

Novartis Investigative Site, Seville

51092

Novartis Investigative Site, Reims

56126

Novartis Investigative Site, Pisa

69437

Novartis Investigative Site, Lyon

75015

Novartis Investigative Site, Paris

80045

University of Colorado Univ Colorado, Aurora

90048

Cedars Sinai Medical Center SC-3, Los Angeles

420029

Novartis Investigative Site, Kazan'

40536-0098

University of Kentucky Univ Kebtucky, Lexington

00189

Novartis Investigative Site, Roma

1105 AZ

Novartis Investigative Site, Amsterdam

9713 GZ

Novartis Investigative Site, Groningen

08035

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

G11 6NT

Novartis Investigative Site, Glasgow

NW3 2QG

Novartis Investigative Site, London

SE1 9RT

Novartis Investigative Site, London

M20 9BX

Novartis Investigative Site, Manchester

S10 2SJ

Novartis Investigative Site, Sheffield